JPWO2020157692A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020157692A5 JPWO2020157692A5 JP2021544518A JP2021544518A JPWO2020157692A5 JP WO2020157692 A5 JPWO2020157692 A5 JP WO2020157692A5 JP 2021544518 A JP2021544518 A JP 2021544518A JP 2021544518 A JP2021544518 A JP 2021544518A JP WO2020157692 A5 JPWO2020157692 A5 JP WO2020157692A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- composition
- compound
- hiv infection
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 208000031886 HIV Infections Diseases 0.000 claims description 8
- 208000037357 HIV infectious disease Diseases 0.000 claims description 8
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- -1 victegravir Chemical compound 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 5
- 229950005928 cabotegravir Drugs 0.000 claims description 4
- WCWSTNLSLKSJPK-LKFCYVNXSA-N cabotegravir Chemical compound C([C@H]1OC[C@@H](N1C(=O)C1=C(O)C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F WCWSTNLSLKSJPK-LKFCYVNXSA-N 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 229960002542 dolutegravir Drugs 0.000 claims description 4
- RHWKPHLQXYSBKR-BMIGLBTASA-N dolutegravir Chemical compound C([C@@H]1OCC[C@H](N1C(=O)C1=C(O)C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F RHWKPHLQXYSBKR-BMIGLBTASA-N 0.000 claims description 4
- SWMDAPWAQQTBOG-UHFFFAOYSA-N fostemsavir Chemical compound C1=2N(COP(O)(O)=O)C=C(C(=O)C(=O)N3CCN(CC3)C(=O)C=3C=CC=CC=3)C=2C(OC)=CN=C1N1C=NC(C)=N1 SWMDAPWAQQTBOG-UHFFFAOYSA-N 0.000 claims description 4
- 229950010812 fostemsavir Drugs 0.000 claims description 4
- 238000010255 intramuscular injection Methods 0.000 claims description 4
- 239000007927 intramuscular injection Substances 0.000 claims description 4
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims description 4
- 229960001627 lamivudine Drugs 0.000 claims description 4
- 238000010254 subcutaneous injection Methods 0.000 claims description 4
- 239000007929 subcutaneous injection Substances 0.000 claims description 4
- ZIAOVIPSKUPPQW-UHFFFAOYSA-N 3-chloro-5-[1-[(4-methyl-5-oxo-1h-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)pyridin-3-yl]oxybenzonitrile Chemical compound N1C(=O)N(C)C(CN2C(C(OC=3C=C(C=C(Cl)C=3)C#N)=C(C=C2)C(F)(F)F)=O)=N1 ZIAOVIPSKUPPQW-UHFFFAOYSA-N 0.000 claims description 2
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 claims description 2
- 108010019625 Atazanavir Sulfate Proteins 0.000 claims description 2
- 229960003277 atazanavir Drugs 0.000 claims description 2
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 claims description 2
- 229960005107 darunavir Drugs 0.000 claims description 2
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 claims description 2
- 229950003141 doravirine Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229960004710 maraviroc Drugs 0.000 claims description 2
- GSNHKUDZZFZSJB-QYOOZWMWSA-N maraviroc Chemical compound CC(C)C1=NN=C(C)N1[C@@H]1C[C@H](N2CC[C@H](NC(=O)C3CCC(F)(F)CC3)C=3C=CC=CC=3)CC[C@H]2C1 GSNHKUDZZFZSJB-QYOOZWMWSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- LDEKQSIMHVQZJK-CAQYMETFSA-N tenofovir alafenamide Chemical compound O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1 LDEKQSIMHVQZJK-CAQYMETFSA-N 0.000 claims description 2
- 229960004946 tenofovir alafenamide Drugs 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 description 6
- 102000009666 Cytochrome P-450 CYP2B6 Human genes 0.000 description 4
- 108010020070 Cytochrome P-450 CYP2B6 Proteins 0.000 description 4
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical class C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 3
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 229960003804 efavirenz Drugs 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229950004159 bictegravir Drugs 0.000 description 1
- SOLUWJRYJLAZCX-LYOVBCGYSA-N bictegravir Chemical compound C([C@H]1O[C@@H]2CC[C@@H](C2)N1C(=O)C1=C(C2=O)O)N1C=C2C(=O)NCC1=C(F)C=C(F)C=C1F SOLUWJRYJLAZCX-LYOVBCGYSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000019525 primary metabolic process Effects 0.000 description 1
- 229930010796 primary metabolite Natural products 0.000 description 1
- 230000024053 secondary metabolic process Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962799800P | 2019-02-01 | 2019-02-01 | |
| US62/799,800 | 2019-02-01 | ||
| PCT/IB2020/050743 WO2020157692A1 (en) | 2019-02-01 | 2020-01-30 | Inhibitors of human immunodeficiency virus replication |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022523726A JP2022523726A (ja) | 2022-04-26 |
| JPWO2020157692A5 true JPWO2020157692A5 (https=) | 2023-01-26 |
| JP2022523726A5 JP2022523726A5 (https=) | 2023-01-26 |
Family
ID=69528890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021544518A Ceased JP2022523726A (ja) | 2019-02-01 | 2020-01-30 | ヒト免疫不全ウイルス複製の阻害剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220105096A1 (https=) |
| EP (1) | EP3917930B1 (https=) |
| JP (1) | JP2022523726A (https=) |
| AR (1) | AR117920A1 (https=) |
| ES (1) | ES2941240T3 (https=) |
| PT (1) | PT3917930T (https=) |
| TW (1) | TW202045502A (https=) |
| UY (1) | UY38559A (https=) |
| WO (1) | WO2020157692A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021004593A (es) | 2018-10-24 | 2021-06-15 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicacion del virus de la inmunodeficiencia humana. |
| LT3986561T (lt) * | 2019-06-19 | 2024-04-25 | VIIV Healthcare UK (No.5) Limited | Pirido[2,3-d]pirimidino dariniai kaip žmogaus imunodeficito viruso replikacijos inhibitoriai |
| TW202128648A (zh) * | 2019-10-04 | 2021-08-01 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| TWI902729B (zh) | 2019-11-28 | 2025-11-01 | 日商鹽野義製藥股份有限公司 | 以組合整合酶阻礙劑及抗ｈｉｖ藥為特徵之ｈｉｖ感染症的預防及治療用醫藥 |
| UY38982A (es) * | 2019-12-09 | 2021-06-30 | Viiv Healthcare Co | Composiciones farmacéuticas |
| KR20220151655A (ko) * | 2020-03-06 | 2022-11-15 | 비브 헬스케어 유케이 (넘버5) 리미티드 | 인간 면역결핍 바이러스 복제의 억제제 |
| CN115397424A (zh) * | 2020-04-15 | 2022-11-25 | Viiv保健英国第五有限公司 | 人类免疫缺陷病毒复制的抑制剂 |
| US20250042926A1 (en) | 2023-05-31 | 2025-02-06 | Gilead Sciences, Inc. | Therapeutic compounds for hiv |
| AR132951A1 (es) | 2023-06-15 | 2025-08-13 | Viiv Healthcare Uk No 5 Ltd | Métodos e intermedios para preparar compuestos |
| US12594276B2 (en) | 2024-02-05 | 2026-04-07 | Viiv Healthcare Uk (No. 5) Limited | Inhibitors of human immunodeficiency virus replication |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102464654B (zh) | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| EP2729448B1 (en) | 2011-07-06 | 2015-09-09 | Gilead Sciences, Inc. | Compounds for the treatment of hiv |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| CA2897268C (en) | 2013-01-09 | 2018-12-04 | Gilead Sciences, Inc. | Therapeutic compounds for the treatment of viral infections |
| TW201443037A (zh) | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| CA2896244C (en) | 2013-01-09 | 2017-07-04 | Gilead Sciences, Inc. | 5-membered heteroaryls and their use as antiviral agents |
| TWI694071B (zh) | 2013-03-01 | 2020-05-21 | 美商基利科學股份有限公司 | 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物 |
| EP3060554A1 (en) | 2013-10-24 | 2016-08-31 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| WO2015130964A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Therapeutic compounds |
| WO2015130966A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Antiviral agents |
| PT3186239T (pt) | 2014-08-29 | 2019-01-10 | Gilead Sciences Inc | Agentes antirretrovirais |
| US9855230B2 (en) | 2014-09-09 | 2018-01-02 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| BR112017022605A2 (pt) | 2015-04-23 | 2018-07-17 | Viiv Healthcare Uk No 5 Ltd | ?composto, composição, e, método para tratamento de infecção por hiv?. |
| CN107995910A (zh) | 2015-04-23 | 2018-05-04 | Viiv保健英国第五有限公司 | 人免疫缺陷病毒复制的抑制剂 |
| KR20230011471A (ko) | 2016-08-19 | 2023-01-20 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물 |
| TW201906834A (zh) * | 2017-05-02 | 2019-02-16 | 英商Viiv醫療保健英國(No.5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| TWI687415B (zh) | 2017-08-17 | 2020-03-11 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| US10836746B2 (en) | 2018-02-15 | 2020-11-17 | Gilead Sciences, Inc. | Therapeutic compounds |
| WO2019161280A1 (en) | 2018-02-16 | 2019-08-22 | Gilead Sciences, Inc. | Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection |
| WO2019198024A1 (en) | 2018-04-11 | 2019-10-17 | VIIV Healthcare UK (No.5) Limited | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication |
-
2020
- 2020-01-29 UY UY0001038559A patent/UY38559A/es not_active Application Discontinuation
- 2020-01-30 ES ES20704596T patent/ES2941240T3/es active Active
- 2020-01-30 JP JP2021544518A patent/JP2022523726A/ja not_active Ceased
- 2020-01-30 EP EP20704596.4A patent/EP3917930B1/en active Active
- 2020-01-30 US US17/425,796 patent/US20220105096A1/en not_active Abandoned
- 2020-01-30 AR ARP200100242A patent/AR117920A1/es not_active Application Discontinuation
- 2020-01-30 PT PT207045964T patent/PT3917930T/pt unknown
- 2020-01-30 TW TW109102689A patent/TW202045502A/zh unknown
- 2020-01-30 WO PCT/IB2020/050743 patent/WO2020157692A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Feighner et al. | Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression | |
| DK168514B1 (da) | Synergistisk produkt indeholdende en kombination af amantadin og selegilin, fremgangsmåde til fremstilling af produktet og anvendelse af amantadin og selegilin til fremstilling af produktet | |
| JPWO2020157692A5 (https=) | ||
| CL2024003601A1 (es) | Nuevas combinaciones terapéuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| JP2016505561A5 (https=) | ||
| JP2011512399A (ja) | 卵巣癌を治療するための、パクリタキセルを含む配合剤 | |
| US20040152625A1 (en) | Method for improving the pharmacokinetics of an NNRTI | |
| EP3833378B1 (en) | Treatment of warts | |
| UA123780C2 (uk) | Лікування екземи кистей | |
| JPWO2020254985A5 (https=) | ||
| US20030166696A1 (en) | Pramipexole for the treatment of HIV dementia | |
| IL319451A (en) | HIV treatment with CABOTEGRAVIR and RILPIVIRINE in pediatric patients | |
| JPWO2020222108A5 (https=) | ||
| KR20230015320A (ko) | 감염성 질환의 치료에서의 부실라민의 용도 | |
| Stevens et al. | (382) Safety and Tolerability of CNTX-4975 in Subjects with Chronic, Moderate to Severe Knee Pain Associated With Osteoarthritis (OA): A Pilot Study | |
| Shahani et al. | Status of chloroquine and hydroxychloroquine in COVID-19 infection | |
| Pariser et al. | Efficacy and safety of onychomycosis treatments: an evidence-based overview | |
| CN110279691A (zh) | 一种外科术后护理镇痛药物及其用途 | |
| JPWO2021070054A5 (https=) | ||
| Stevens et al. | (384) CNTX-4975 (Trans-Capsaicin) Injection Provides Clinically Meaningful Pain Reduction in Subjects with Painful Intermetatarsal Neuroma (Morton’s Neuroma): A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study | |
| JPWO2021064618A5 (https=) | ||
| AL IDRISSI et al. | Chloroquineand hydroxychloroquine in covid 19: asystematic review | |
| Juan et al. | (381) S3 transforaminal epidural steroid injections as treatment of chronic testicular pain | |
| TW202214232A (zh) | 一種組合物的醫藥用途 | |
| NZ773583B2 (en) | Methods of treating psoriasis |